Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147381 | 1.00 | CYP2A6 (0.52) | CYP2A6ALDH1A1CYP3A4CYP1A2BTK | |
| SCHEMBL8258328 | 0.80 | MAP2K4 (0.59) | IDO1LRRK2 | |
| SCHEMBL3594723 | 0.78 | CDC7 (0.42) | CYP2A6ALDH1A1CYP3A4CYP1A2BTK | |
| SCHEMBL13545618 | 0.78 | RAB9A (0.64) | ALDH1A1KDM4EMAPTHSD17B10HPGDS | |
| SCHEMBL6775760 | 0.77 | MEN1 (0.45) | CYP2A6ALDH1A1CYP3A4CYP1A2MAPT | |
| SCHEMBL4950 | 0.77 | NR1H2 (0.43) | ALDH1A1CYP1A2BTKKDM4ELMNA | |
| SCHEMBL1422975 | 0.77 | CHRNB2 (0.59) | ALDH1A1CYP3A4CYP1A2KDM4ESMN1; SMN2 | |
| SCHEMBL1423544 | 0.77 | CHRNB2 (0.59) | ALDH1A1CYP3A4CYP1A2KDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1423322 | 0.76 | CHRNB2 (0.58) | ALDH1A1CYP3A4CYP1A2KDM4ESMN1; SMN2 | |
| SCHEMBL7383016 | 0.75 | EPHX2 (0.38) | CYP2A6ALDH1A1CYP3A4CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117399072-A | Ultra-small cerium-based metal organic framework nano enzyme and preparation method and application thereof | 华南理工大学 | 2024-01-16 | — | — | CN | claimed |
| CN-117106189-A | Metal organic framework artificial hydrolase and preparation method and application thereof | 华南理工大学 | 2023-11-24 | — | — | CN | claimed |
| CN-105017239-A | Cu(I)-based metal organic framework, and preparation method and applications thereof | UNIV SHANDONG NORMAL | 2015-11-04 | — | — | CN | claimed |
| US-20090018123-A1 | Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation | SINDKHEDKAR MILIND D | 2009-01-15 | — | — | US | claimed |
| EP-1912980-A2 | OXAZOLIDINONES BEARING ANTIMICROBIAL ACTIVITY COMPOSITION AND METHODS OF PREPARATION | Wockhardt Limited (IN) | 2008-04-23 | — | — | EP | claimed |
| WO-2007023507-A2 | OXAZOLIDINONES BEARING ANTIMICROBIAL ACTIVITY COMPOSITION AND METHODS OF PREPARATION | WOCKHARDT LIMITED (IN) | 2007-03-01 | — | — | WO | claimed |
| US-20250034153-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-01-30 | — | — | US | disclosed |
| US-20240368131-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-11993729-B2 | Chemical mechanical polishing composition | BASF SE (DE) | 2024-05-28 | — | — | US | disclosed |
| CN-117106189-A | Metal organic framework artificial hydrolase and preparation method and application thereof | 华南理工大学 | 2023-11-24 | — | — | CN | disclosed |
| US-20230160904-A1 | REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230124485-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2023-04-20 | — | — | US | disclosed |
| EP-4154009-A1 | REAGENT FOR MASS SPECTROMETRY | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| EP-0296721-B1 | HETEROCYCLIC COMPOUNDS | H. LUNDBECK A/S (DK) | 1993-06-23 | — | — | EP | disclosed |
| US-4925858-A | NERVOUS SYSTEM DISORDERS, ALZHEIMER*S DISEASE | H. LUNDBECK A/S (DK) | 1990-05-15 | — | — | US | disclosed |
| US-4866077-A | TREATMENT OF NERVOUS SYSTEM DISORDERS SUCH AS ALZHEIMER*S DISEASE | H. LUNDBECK A/S (DK) | 1989-09-12 | — | — | US | disclosed |
| EP-0296721-A2 | Heterocyclic compounds | H. LUNDBECK A/S (DK) | 1988-12-28 | — | — | EP | disclosed |
| US-4058619-A | Thiophene derivatives having antilipolytic activity | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-11-15 | — | — | US | disclosed |
| US-4031236-A | ANTILIPOLYTIC AGENTS, FREE FATTY ACIDS | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-06-21 | — | — | US | disclosed |
| US-4021450-A | ANTILIPOLYTIC ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124485-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | CYP2A6 694/4885ALDH1A1 498/4885CYP3A4 1298/4885 |
| US-20090018123-A1 | Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation | POLL, POLM, POLRMT | CYP2A6 1766/4885ALDH1A1 1847/4885CYP3A4 1583/4885 |
| US-20240368131-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, NOD1 | CYP2A6 2638/4885ALDH1A1 4026/4885CYP3A4 604/4885 |
| US-20230160904-A1 | REAGENT FOR MASS SPECTROMETRY | SRMS, AKR7A2, PTMS | CYP2A6 94/4885ALDH1A1 42/4885CYP3A4 31/4885 |
| US-20250034153-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | CYP2A6 694/4885ALDH1A1 498/4885CYP3A4 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.